EFFICACY OF STANDARD CARE FOR SECOND-LINE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) BY KRAS MUTATION STATUS: OBSERVATIONS ON MEK INHIBITOR ENHANCEMENT OF CHEMOTHERAPY

作者： Pasi A Jaenne , Delyth Clemett , Helen Mann , Ian Smith